Propanc Biopharma Approves $5 Million Buyback Ahead of PRP Phase 1b Trial
PPCB•Propanc Biopharma approved a $5.0 million share repurchase program under Rule 10b5-1, allowing flexible buybacks via open-market, block trades or accelerated repurchases. Its lead candidate PRP is set to enter a pivotal Phase 1b first-in-human study in 30–40 advanced cancer patients, backed by FDA orphan drug exclusivity.
1. Share Repurchase Program
Propanc Biopharma authorized a program to repurchase up to $5.0 million of its common stock under Rule 10b5-1, without obligating the company to acquire any specific number of shares. Management may execute open-market purchases, block trades, accelerated repurchase transactions or other methods, with the flexibility to modify, suspend or discontinue the program based on market conditions and intrinsic value assessments.
2. PRP Phase 1b Trial Plans
The company’s lead asset, PRP, is advancing into a pivotal Phase 1b first-in-human study targeting 30–40 patients with metastatic solid tumors. Recent milestones include key scientific data publications, patent filings and strategic partnerships with CROs, CDMOs and suppliers to streamline trial initiation and support meaningful clinical progress.
3. Orphan Drug Designation Impact
PRP has received FDA orphan drug designation for pancreatic cancer, providing seven years of market exclusivity upon approval. This status strengthens Propanc’s valuation thesis and underscores management’s view that the current share price does not fully reflect the therapy’s long-term potential.
